Theraclion Statistics
Total Valuation
Theraclion has a market cap or net worth of EUR 16.61 million. The enterprise value is 20.02 million.
Market Cap | 16.61M |
Enterprise Value | 20.02M |
Important Dates
The last earnings date was Thursday, June 26, 2025.
Earnings Date | Jun 26, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Theraclion has 46.26 million shares outstanding. The number of shares has increased by 1.16% in one year.
Current Share Class | 46.26M |
Shares Outstanding | 46.26M |
Shares Change (YoY) | +1.16% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 19.01% |
Owned by Institutions (%) | 7.04% |
Float | 24.10M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 20.01 |
PB Ratio | -145,689.98 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -3.48 |
EV / Sales | 24.11 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -6.64 |
Financial Position
The company has a current ratio of 2.55
Current Ratio | 2.55 |
Quick Ratio | 1.87 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -2.52 |
Interest Coverage | -316.61 |
Financial Efficiency
Return on equity (ROE) is -203.90% and return on invested capital (ROIC) is -39.71%.
Return on Equity (ROE) | -203.90% |
Return on Assets (ROA) | -28.29% |
Return on Invested Capital (ROIC) | -39.71% |
Return on Capital Employed (ROCE) | -82.96% |
Revenue Per Employee | 25,944 |
Profits Per Employee | -179,910 |
Employee Count | 32 |
Asset Turnover | 0.06 |
Inventory Turnover | 1.80 |
Taxes
Income Tax | -983,691 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.12% in the last 52 weeks. The beta is -0.01, so Theraclion's price volatility has been lower than the market average.
Beta (5Y) | -0.01 |
52-Week Price Change | +10.12% |
50-Day Moving Average | 0.30 |
200-Day Moving Average | 0.28 |
Relative Strength Index (RSI) | 65.92 |
Average Volume (20 Days) | 29,199 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Theraclion had revenue of EUR 830,209 and -5.76 million in losses. Loss per share was -0.12.
Revenue | 830,209 |
Gross Profit | -3.83M |
Operating Income | -6.82M |
Pretax Income | -6.74M |
Net Income | -5.76M |
EBITDA | -6.50M |
EBIT | -6.82M |
Loss Per Share | -0.12 |
Balance Sheet
The company has 4.17 million in cash and 7.58 million in debt, giving a net cash position of -3.41 million or -0.07 per share.
Cash & Cash Equivalents | 4.17M |
Total Debt | 7.58M |
Net Cash | -3.41M |
Net Cash Per Share | -0.07 |
Equity (Book Value) | -114 |
Book Value Per Share | -0.00 |
Working Capital | 5.02M |
Cash Flow
In the last 12 months, operating cash flow was -2.91 million and capital expenditures -102,000, giving a free cash flow of -3.01 million.
Operating Cash Flow | -2.91M |
Capital Expenditures | -102,000 |
Free Cash Flow | -3.01M |
FCF Per Share | -0.07 |
Margins
Gross Margin | n/a |
Operating Margin | -821.37% |
Pretax Margin | -811.94% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Theraclion does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.16% |
Shareholder Yield | n/a |
Earnings Yield | -34.66% |
FCF Yield | -18.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Theraclion has an Altman Z-Score of -1.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.17 |
Piotroski F-Score | 2 |